EHCHealthcare · Medical Care FacilitiesThe 13 Wall Street analysts covering Encompass Health Corp. hold a median 12-month price target of $150 — +18.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Encompass Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (91): Analysts have, on balance, been raising their forecasts.
Accruals (53): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on EHC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +18.5% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | TD Cowen | Maintains | Buy | $125 → $140 |
| 7 Aug 2026 | Truist Securities | Maintains | Buy | $140 → $150 |
| 7 Aug 2026 | UBS | Maintains | Buy | $150 → $155 |
| 6 Aug 2026 | Barclays | Maintains | Overweight | $140 → $144 |
| 28 May 2026 | TD Cowen | Initiates | Buy | $125 |
| 28 May 2026 | TD Cowen | Initiates | Buy | — |
| 5 May 2026 | Barclays | Maintains | Overweight | — |
| 6 Feb 2026 | Barclays | Maintains | Overweight | — |
| 30 Oct 2025 | Barclays | Maintains | Overweight | — |
| 2 Oct 2025 | UBS | Maintains | Buy | — |
| 16 Sept 2025 | Keybanc | Maintains | Overweight | — |
| 10 Sept 2025 | B of A Securities | Maintains | Buy | — |
| 14 Aug 2025 | Truist Securities | Maintains | Buy | — |
| 6 Aug 2025 | UBS | Maintains | Buy | — |
| 5 June 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 27 May 2025 | Keybanc | Maintains | Overweight | — |
| 28 Apr 2025 | RBC Capital | Maintains | Outperform | — |
| 28 Apr 2025 | Truist Securities | Reiterates | Buy | — |
| 28 Apr 2025 | UBS | Maintains | Buy | — |
| 25 Apr 2025 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EHC appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Encompass Health Corp. returned +3.7% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 36% of US stocks
Cheaper than 52% of US stocks
Cheaper than 21% of US stocks
Cheaper than 34% of US stocks
Higher than 51% of US stocks
Higher than 45% of US stocks
Higher than 98% of US stocks
Higher than 76% of US stocks
Higher than 70% of US stocks
Higher than 85% of US stocks
Higher than 92% of US stocks
Higher than 67% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Encompass Health Corp. has a market value of $12.3B and an enterprise value of $15.9B.
Revenue in the twelve months to 30 June 2026: $6.2B. The latest quarter grew 9.6% year on year.
Net income over the same four quarters: $833.3M, a 13.4% net margin.
Diluted earnings per share, trailing twelve months: $6.14.
Free cash flow in the twelve months to 30 June 2026: $413.4M.
Encompass Health Corp. spent $247.0M on share buybacks and $75.2M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 20.8×; forward P/E: 18.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.68%, paying out 13% of earnings.
Encompass Health Corp. employs 29,699 people — $209K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Encompass Health Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research’s headline characterizes Encompass Health as a top value stock for the long term. The excerpt points readers to Zacks Style Scores as a way to identify stocks, without providing details about EHC’s score or analysis.
Why it matters — EHC watchers may note the favorable value-stock framing, though the excerpt gives no supporting specifics about the company.
Encompass Health opened a 50-bed rehabilitation hospital in Maine, expanding its footprint. The item also cites strong discharge growth and planned openings as supporting capacity expansion.
Why it matters — The new hospital and planned openings are relevant to EHC watchers tracking the company’s capacity and footprint expansion.
Encompass Health announced that its Rehabilitation Hospital of Bangor is now open in Bangor, Maine.
Why it matters — The opening adds a newly operating Encompass Health inpatient rehabilitation hospital in Maine.
Zacks Investment Research highlights Encompass Health as a strong growth stock, citing its Zacks Style Scores as a way to identify market-beating stocks. The piece frames Encompass Health favourably within Zacks' growth-stock criteria.
Why it matters — A positive growth-stock designation from Zacks may draw more attention to EHC and reinforce investor confidence in its fundamentals.
Encompass Health Corp. announced that it will report results for its third quarter ended Sept. 30, 2026. The company said it will also hold an earnings call related to those results.
Why it matters — The announcement lets Encompass Health watchers know when to expect the company's third-quarter financial results and earnings call.
The 13 Wall Street analysts covering Encompass Health Corp. have a median 12-month price target of $150, with estimates ranging from $140 to $155. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Encompass Health Corp., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Encompass Health Corp. 83 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Encompass Health Corp. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (91 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +18.5% from the last close, and Ticker Nerd's factor model ranks Encompass Health Corp. 83 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Encompass Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $140 to $155 over the next 12 months.
Encompass Health Corp. returned +3.7% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Encompass Health Corporation is a post-acute healthcare company focused on inpatient rehabilitation hospitals. The company provides specialized, facility-based care for patients recovering from strokes, neurological disorders, brain and spinal cord injuries, cardiac and pulmonary conditions, complex orthopedic cases, amputations, and other serious illnesses or injuries.
The most recent item we track (Zacks Investment Research, 9 Oct 2026): "Why Encompass Health (EHC) is a Top Value Stock for the Long-Term". Zacks Investment Research’s headline characterizes Encompass Health as a top value stock for the long term. The excerpt points readers to Zacks Style Scores as a way to identify stocks, without providing details about EHC’s score or analysis.
Encompass Health Corporation is a post-acute healthcare company focused on inpatient rehabilitation hospitals. The company provides specialized, facility-based care for patients recovering from strokes, neurological disorders, brain and spinal cord injuries, cardiac and pulmonary conditions, complex orthopedic cases, amputations, and other serious illnesses or injuries. Its services combine medical, nursing, therapy, and ancillary support to help patients regain functional ability, independence, and quality of life. Encompass Health operates a national network of rehabilitation hospitals across the United States and Puerto Rico, making it a significant provider in the inpatient rehabilitation market. Based in Birmingham, Alabama, Encompass Health plays a central role in delivering coordinated recovery care for patients who need intensive, medically supervised rehabilitation after hospitalization.
CEO Mr. Mark J. Tarr · 29,699 employees · United States · https://www.encompasshealth.com
